



PHOENIX GROUP

Proposed acquisition of Standard Life Assurance and Strategic Partnership with Standard Life Aberdeen plc

23 February 2018

Agenda

Transaction overview

Clive Bannister | Group Chief Executive

FY17 performance and financial benefits of transaction

Jim McConville | Group Finance Director

Conclusion and Q&A


Clive Bannister | Group Chief Executive



Transaction overview

Clive Bannister


Phoenix acquires Standard Life Aberdeen's UK and European life business for £2.9 billion - both parties enter a long-term Strategic Partnership







Consideration of £2,930 million⁽²⁾ is equivalent to 84% Own Funds⁽³⁾

- (1) Acquired businesses include Standard Life Assurance Limited and Vebnet Limited (together "Standard Life Assurance")
- (2) Consideration and Own Funds are stated following deduction of a pre completion dividend to Standard Life Aberdeen of £312m. In the event that the acquisition completes after Phoenix's 2018 interim ex-dividend date, there will be an additional payment of the amount of the dividend that Standard Life Aberdeen would otherwise have received
- (3) Own Funds of £3.5bn. Price includes £1,971m of cash consideration and the £959m value of the proposed 19.99% Standard Life Aberdeen shareholding based on Phoenix's market capitalisation of £2,888m as at 22 February 2018 (after deducting an assumed Final dividend for 2017 of 25.1p per share) and assumes a Rights Issue of £950m before expenses

Two companies doing what they do best: The largest Closed Life Consolidator in Europe and a world class Global Investment Manager with a UK wealth platform




The transaction results in a bigger and better Phoenix – all key metrics are improved



(1) Estimated position as at 31 December 2017. Solvency II surplus of Combined Group assumes £600m of hybrid debt, with the remaining debt finance being senior debt. Subject to regulatory approval of the Internal Model treatment

Attractive pricing and efficient financing structure

Price/Own Funds⁽¹⁾



Consideration and valuation

- Price of £2,930 million
- Price to Own Funds of 84%⁽¹⁾
- Acquisition consideration consisting of cash of £1,971 million and stake of 19.99% in enlarged group

Capital raisings

- Capital raisings to fund cash consideration of £1,971 million:
 - Fully underwritten Rights Issue on a standby basis to raise £950 million
 - Remaining cash consideration of £1,021 million to be financed from £1,500 million underwritten debt facilities and up to £250 million of own cash resources
- Intention to refinance senior acquisition funding into hybrid capital through the capital markets

(1) Valuation metric based on consideration of £2,930m and Solvency II Own Funds of £3.5bn as at FY17. Solvency II Own Funds excludes unsupported with profits funds. Consideration and Own Funds are stated following deduction of a pre completion dividend to Standard Life Aberdeen of £312m

Transaction underpinned by strong governance structure

Phoenix Group Holdings

- 2 Directors appointed by Standard Life Aberdeen to join existing PGH Board due to 19.99% shareholding
- PGH onshoring process to be progressed following the completion of transaction

Life company governance

- Identical Board composition for all life companies in enlarged Group
- Dedicated support unit for Client Service and Proposition Agreement

Relationship Agreement


- Post completion 19.99% Standard Life Aberdeen shareholding, with 12 month lock-up agreement and 2 year standstill
- Right to appoint 2 Directors above 15% and 1 Director above 10% shareholding
- Phoenix to act independently of Standard Life Aberdeen

Transaction provides optionality to participate in sizeable and emerging European life insurance consolidation

Significant new market opportunity

- Increases potential market opportunity for Phoenix from c.£380 billion in the UK to c.£540 billion including Germany and Ireland
- European life markets highly fragmented and nascent in terms of consolidation
- Product and market similarities allow Phoenix to leverage existing capabilities
- German & Irish entities will require a Part VII transfer to move from branch of UK entity into Irish subsidiary

Increased market size (by assets)⁽¹⁾



(1) Source: Phoenix analysis

Strategic rationale underpinned by alignment to all of Phoenix's M&A criteria

Closed life focus	<ul style="list-style-type: none">✓ Provides in-force business with £166 billion of assets and 4.8 million policyholders✓ Fully aligned with Phoenix's existing UK product mix – delivers increased scale and efficiency✓ Provides base for participation in future European closed fund consolidation
Value accretive	<ul style="list-style-type: none">✓ Total expected cashflow generation of £5.5 billion from acquisition✓ Net value of cost and capital synergies of £720 million
Supports the dividend	<ul style="list-style-type: none">✓ Increased dividend with enhanced sustainability✓ Growth from assets generated through Client Service and Proposition Agreement
Maintains investment grade rating	<ul style="list-style-type: none">✓ Increase in Solvency II surplus to £2.5 billion, 147% coverage ratio⁽¹⁾✓ Leverage maintained in 25-30% target range (on Fitch Ratings basis)

(1) Estimated position as at 31 December 2017. Shareholder Capital Coverage Ratio excludes Own Funds and SCR of unsupported with profits funds and PGL Pension Scheme. Solvency II surplus of Combined Group subject to regulatory approval of the Internal Model treatment



FY17 performance and financial benefits of transaction

Jim McConville

Key FY17 highlights: a strong performance for Phoenix in 2017

Strong financial performance

- Cash generation of £653 million in FY17
- On track to be at the top end of the range for the £1.0 - £1.2 billion cash generation target for 2017 – 2018
- Estimated PGH Solvency II surplus of £1.8 billion, 164% coverage ratio

Integrations substantially complete

- Capital and cost synergies ahead of plan
- Cashflow of £282 million from AXA and £236 million from Abbey Life to date
- Combined cost synergies of £27 million p.a., £10 million p.a. higher than originally announced

Strengthened balance sheet

- Issuance of £835 million of Tier 2 and Tier 3 subordinated debt
- Full repayment of RCF in August 2017
- Rating upgrade from Fitch Ratings in July 2017 to A+⁽¹⁾

(1) Insurer Financial Strength rating of Phoenix Life Limited and Phoenix Life Assurance Limited

Proven track record of integration: AXA and Abbey Life integration close to completion and with greater than planned benefits

1 Cash flows	AXA Wealth	2016 - 2020	2021+	✓	Delivered £282m to FY17	
		£0.3bn	£0.2bn			
	Abbey Life	2016 - 2020	2021+	✓	Delivered £236m to FY17	
		£0.5bn	£1.1bn			
2 Cost synergies	AXA Wealth	£10m p.a. by FY17		✓	£17m p.a. savings now delivered (+70%)	
	Abbey Life	£7m p.a. by HY18		✓	£10m p.a. savings from Q1 2018 (+40%)	
	3 Finance and Actuarial systems	9 at FY16 → 3 at HY18			✓	On track to hit target at Q1 2018

The transaction materially enhances cash generation, and results in an increase in scale and capital resources


Figures as of FY17, unless otherwise stated

	Phoenix	Standard Life Assurance	Combined
Cash generation (2018+)	£6.3bn	£5.5bn	£11.8bn
Solvency II surplus capital ⁽¹⁾	£1.8bn	£1.0bn	£2.5bn
Solvency II coverage ratio ⁽¹⁾	164%	143%	147%
Assets ⁽¹⁾	£74bn	£166bn	£240bn
Policyholders	5.6m	4.8m	10.4m

(1) Estimated position. Solvency II coverage ratio on Shareholder Capital basis. Solvency II surplus of Combined Group assumes £600m of hybrid debt and is subject to regulatory approval of the Internal Model treatment

Total future in-force cashflows increase to £11.8 billion


Future cash generation from in-force business



- Phoenix achieved £653 million cash generation in FY17, with new Phoenix target of £2.5 billion between 2018-2022
- Total cashflow of £5.5 billion expected to be generated from Standard Life Assurance's in-force book
- £1.0 billion of cash generation from acquisition between 2018-2022
- Extended cashflows post 2022, with scope for incremental management actions

Significant potential for cost and capital synergies

Indicative net value of synergies⁽¹⁾




(1) Value of cost synergies calculated after tax and capitalised over 10 years

Sources of synergies

- **Cost savings of £50 million p.a. (pre tax):**
 - Combination of life company management and support functions
 - Leverage Phoenix operating model
- **Capital synergies and management actions of £440 million:**
 - Hedging of unit-linked VIF
 - Application of Phoenix's Strategic Asset Allocation to annuity portfolio
- **Integration costs:**
 - Total post-tax costs expected to be £135 million

Cash generation builds holding company cash and supports dividend

Combined Group: Illustrative uses of cash from 2018 - 2022



(1) Phoenix FY17 holding company cash of £535m

(2) £2.5bn 2018-2022 Phoenix cash generation target, with a further £1.0bn expected from the Standard Life Assurance acquisition


(3) Illustrative Phoenix operating expenses of £35m p.a. over 2018 to 2022. Phoenix pension scheme contributions estimated in line with current funding agreements, comprising £150m in respect of the Pearl scheme and £44m in respect of the Abbey Life scheme. Assumes integration costs of £135m

(4) Includes interest on the Group's listed bonds, excluding interest on PLL Tier 2 bonds which are incurred directly by Phoenix Life Limited. Acquisition debt assumed to be £1,021m and issued at the existing average cost of debt. Assumes maturing debt during period is refinanced

(5) Illustrative dividend assumed at cost of £263m in 2018 and £338m per annum over 2019 to 2022 (assumes completion of transaction by HY18 results)

Beyond 2022, additional cash generation will enhance sustainability of dividends

Combined Group: Illustrative uses of cash from 2023 onward



- There is an expected £8.3 billion of cash to emerge after 2022
- Strategic Partnership could provide additional value from future new business

(1) Illustrative holding company cash as at FY22 as calculated on previous slide


(2) Total shareholder borrowings of £1,585m as at FY17 plus additional acquisition debt of £1,021m

Delivers an increased dividend with enhanced sustainability

Dividend policy

- Dividend distributions to be increased, with additional cash generation providing enhanced sustainability
- Expected annualised cost of dividend to increase to £338 million as at 2018 Final dividend⁽¹⁾
- Implies a 3% increase in dividend per share⁽¹⁾
- Stable and sustainable dividend policy maintained

Expected dividend distributions⁽¹⁾




(1) Current annualised dividend of 50.2p. The increased annualised cost of £338m approximates to a dividend per share uplift of 3% based on a closing share price of 759.5p on 22 February

Acquisition will increase Solvency II surplus by £0.7 billion

Capital position

- Single harmonised Internal Model planned
- Phoenix will apply hedging strategies to protect capital position from date of announcement
- Capital sensitivities will continue to be resilient following hedging strategies
- Potential for further hybrid debt issuance post completion


Solvency II surplus⁽¹⁾



(1) Estimated position. Solvency II surplus and Shareholder Capital coverage ratio calculated at Phoenix Group Holdings

(2) Pro forma position assumes £600m of hybrid debt, with the remaining debt finance being senior debt. Solvency II surplus of Combined Group subject to regulatory approval of the Internal Model treatment

Opportunity for further value from Client Service and Proposition Agreement in Workplace pensions plus SIPP and drawdown administration



Client Service and Proposition Agreement leverages the unique capabilities of both partners



Conclusion and Q&A

Clive Bannister

This transaction will accelerate the strategic reshaping of the UK life insurance landscape

Life Insurance Specialists

- Balance sheet led business model
- Clear understanding and appetite for traditional insurance risks
- Expertise in product manufacturing and administration
- Investors focused on cash generation and dividends

Distribution / Advice / Asset Management Focused Players

- Capital-light business model with reduced insurance risks
- Focused on future customer proposition
- Expertise in distribution, advice and investment management
- Investors focused on fee-based earnings stream



Phoenix remains focused on closed life consolidation and now has a range of adjacent growth opportunities

Closed fund consolidation

- Continued significant UK opportunity of c.£380 billion
- Additional emerging opportunity in Germany and Ireland of c.£160 billion

Bulk Purchase Annuities

- New Phoenix team in place and approach to pricing has been established
- In exclusive discussions on first external pensions buy-in transaction

Workplace pensions/ SIPP provider

- Product manufacturing and risk underwriting under new Client Service and Proposition Agreement
- Dedicated new business support unit

Vesting annuities

- Continue to write annuities for vesting policyholders
- Complementary to SunLife protection products, with natural longevity hedge

SunLife

- Distribution company in place, with Phoenix Life Limited underwriting risk
- Focus on strengths in marketing and distribution

Expected future timing

Milestones	Timeline
<ul style="list-style-type: none">• Standard Life Assurance acquisition and Strategic Partnership announced	23 February
<ul style="list-style-type: none">• Full year 2017 results announcement	15 March
<ul style="list-style-type: none">• Expected publication of prospectus and circular	Mid April
<ul style="list-style-type: none">• Expected shareholder vote and Rights Issue	Early May
<ul style="list-style-type: none">• Final day of nil paid rights trading	Mid May
<ul style="list-style-type: none">• Expected commencement of trading in new fully paid shares	Mid May
<ul style="list-style-type: none">• Target closing of acquisition, subject to regulatory approvals	Q3 2018

The £2.9 billion acquisition of Standard Life Assurance makes Phoenix the pre-eminent closed life fund consolidator in Europe

Acquisition benefits



Significant increase in cash generation of £5.5 billion from 2018, to a total of £11.8 billion



Increased dividend with enhanced sustainability



Cost and capital synergies to create £720 million of shareholder value



Organic future growth in assets from Client Service and Proposition Agreement



Optionality for future European expansion, with a potential c.£160 billion market opportunity



Attractive pricing and efficient financing structure




Q&A



Appendices

FY17 Solvency II Own Funds and SCR (Shareholder Capital basis)



(1) Estimated position. Solvency II surplus and Shareholder Capital coverage ratio calculated at Phoenix Group Holdings. Shareholder Capital basis excludes Own Funds and SCR of unsupported with profits funds and PGL Pension Scheme.

(2) Estimated position after estimated impact of VAT on investment management fees and transaction costs

(3) Pro forma position assumes £600m of hybrid debt, with the remaining debt finance being senior debt. Solvency II surplus of Combined Group subject to regulatory approval of the Internal Model treatment


Overview of Standard Life Assurance: £166bn of assets

		Legacy book			Legacy book with new business manufacturing		
		UK Mature	Europe	Workplace	Europe	Workplace	Retail
AuA (FY17)		£56bn	£12bn	£21bn	£12bn	£19bn	£46bn
Products		<ul style="list-style-type: none"> ▶ With profits ▶ Annuities ▶ Protection ▶ Pensions ▶ Investment bonds 	<ul style="list-style-type: none"> ▶ Germany: With profits business and annuities ▶ Ireland: Pensions, annuities, protection and life assurance 	<ul style="list-style-type: none"> ▶ Mature back book of with profits products 	<ul style="list-style-type: none"> ▶ Investment products ▶ Off-shore bonds 	<ul style="list-style-type: none"> ▶ Workplace pensions proposition 	<ul style="list-style-type: none"> ▶ Pensions and savings products ▶ Income drawdown proposition

The product mix of both businesses is complementary


Phoenix product mix⁽¹⁾

■ With-profit ■ Unit-linked ■ Annuities and protection



Standard Life Assurance product mix⁽¹⁾

■ With-profit ■ Unit-linked ■ Annuities and protection



(1) Estimated position as at FY17

Overview of current Phoenix debt structure as at FY17

Structure of £1,585 million of outstanding debt as at FY17

Instrument		Issuer/borrower	Maturity	Face value
Bank Debt	Unsecured Revolving Credit Facility (L+110bps) ⁽¹⁾	Phoenix Group Holdings	June 2021	-
Bonds	Unsecured Senior Bond (5.750% due Jul-2021, XS1081768738)	Phoenix Group Holdings	July 2021	£122m
	Subordinated Tier 3 Bond (4.125% due Jul-2022, XS1551285007)	Phoenix Group Holdings	July 2022	£450m
	Subordinated Tier 2 Bond (6.625% due Dec-2025, XS1171593293)	Phoenix Group Holdings	December 2025	£428m
	Subordinated Tier 2 Bond ⁽²⁾ (5.375% due Jul-2027, XS1639849204)	Phoenix Group Holdings	July 2027	US\$500m ⁽³⁾
	Subordinated Tier 2 Bond (7.250% Perpetual NC2021, XS0133173137)	Phoenix Life Limited	March 2021 (first call date)	£200m

Debt maturity profile as at FY17



(1) Revolving Credit Facility has an interest margin of 110bps. In addition, a utilisation fee of 10bps is payable if the RCF is utilised by up to 33% of the £900m facility, 20bps is payable if the RCF is utilised by between 33% and 67% of the £900 million facility, and 40bps if utilised by more than 67% of the £900 million facility. Commitment fees of 35% of margin are payable on undrawn amounts

(2) Swapped into £385m at a semi-annual rate of 4.2% per annum (excluding costs and fees)

Disclaimer and other information

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION

This presentation in relation to Phoenix Group Holdings (the "Company") and its subsidiaries (the "Group") has been prepared solely for use at this presentation. By accepting the materials or attending this presentation, you are agreeing to maintain absolute confidentiality regarding the information disclosed in the presentation and further agree to the following limitations and notifications. The presentation has been provided to you solely for your information and background and is subject to amendment or correction in its entirety. The presentation (or any part of it) may not be reproduced or redistributed, passed on, or the contents otherwise divulged, directly or indirectly, to any other person or published in whole or in part for any purpose without the prior written consent of the Company. Failure to comply with this restriction may constitute a violation of applicable securities laws. The presentation is not directed to, or intended for distribution to or use by, any person or entity that is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would require any registration or licensing within such jurisdiction.

This presentation is for information purposes only and is not intended to and does not constitute or form part of any offer or invitation to purchase or subscribe for, or any solicitation to purchase or subscribe for any securities in any jurisdiction. The information contained herein is only preliminary and indicative and does not purport to contain the information that would be required to evaluate the Company, its financial position and/or any investment decision. This document is not intended to provide, and should not be relied upon for, accounting, legal or tax advice nor does it constitute a recommendation regarding the relevant securities. Accordingly, by attending any presentation in which this document is made available or by receiving this document through any other means, you represent that you are able to receive this document without contravention of any legal or regulatory restrictions applicable to you and will not use this information in relation to any investment decisions (if any). This document is given in conjunction with an oral presentation and should not be taken out of context.

The presentation is not for public release, publication or distribution and should not be distributed, forwarded or transmitted, directly or indirectly, in or into the United States (including its territories and possessions, any State of the United States and the District of Columbia), Australia, Canada, Japan, South Africa or any other jurisdiction where to do so might constitute a violation of local securities laws or regulations. This presentation is not and does not constitute or form a part of any offer of, or solicitation to purchase or subscribe for, any securities in the United States. Any such securities have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "Securities Act"). Any such securities may not be offered or sold in the United States or to, or for the account or benefit of, U.S. persons (as such term is defined in Regulation S under the Securities Act), except pursuant to an exemption from the registration requirements of the Securities Act. No public offering of securities will be made in the United States of America. The distribution of this presentation into jurisdictions other than the United Kingdom may be restricted by law and, therefore, persons into whose possession this presentation comes should inform themselves about and observe any such restrictions. Any failure to comply with any such restrictions may constitute a violation of the securities laws of such jurisdiction. None of the Company and its affiliates, advisors and representatives or any other person accepts liability to any person in relation thereto.

This presentation is addressed only to and directed only at (i) persons who are outside the United Kingdom or (ii) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order") and (iii) high net worth entities, and other persons to whom it may lawfully be communicated, falling within Article 49(2) of the Order (all such persons together being referred to as "relevant persons"). Any investment activity to which this communication relates will only be available to and will only be engaged with, relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents and by accepting this document you represent, warrant and agree that you are a relevant person. In any EEA member state (other than the UK), this presentation is addressed only to and directed solely at "qualified investors" (as defined in EU Directive 2003/71/EC (as amended, including by Directive 2010/73/EU, together with any applicable implementing measures in any Member State, the "Prospectus Directive") in that Member State. This presentation is an advertisement and not a prospectus for the purposes of applicable measures implementing the Prospectus Directive and as such does not constitute an offer to sell or the solicitation of an offer to purchase securities. If any offer were subsequently to be made, no investment decision should be made except solely on the basis of information in a prospectus if one were to be published by the Company in the future. A prospectus may or may not be published by the Company. If published, any such prospectus would include a description of risk factors in relation to an investment in the Company.

No decision has been taken whatsoever to proceed with the offer and sale of securities. Such a decision would be taken only after assessing a number of criteria including feedback and prevailing market conditions. No orders are being taken at this time. Orders could only be placed and accepted during a formal offering period and only after a prospectus had been made available. If a decision is made to proceed with the offer and sale of securities, the offer to acquire securities, and any investment decision should only be made on the basis of information contained in such prospectus, that would, subject to applicable law, be obtainable from the registered office of the Company. The prospectus would supersede all information provided to you before the date of the prospectus, and your investment decision, if any, would have to be made only on the basis of the information contained therein. You should conduct your own independent analysis of all relevant data provided in any prospectus and you are advised to seek expert advice before making any investment decision.

Disclaimer and other information (cont'd)

This presentation may contain certain forward-looking statements, beliefs or opinions, with respect to the financial condition, results of operations and business of the Company, the enlarged Group following the Transaction and the acquired businesses. These statements, which contain the words 'anticipates', 'believes', 'intends', 'will', 'estimates', 'expects', 'may', 'should', 'plans', 'aims', 'seeks', 'continues', 'projected', 'plans', 'goal', 'achieves', 'targets' or other words of similar meaning, reflect the Company's beliefs and expectations and are based on numerous assumptions regarding the Company's present and future business strategies and the environment the Company and the enlarged Group will operate in and are subject to risks and uncertainties that may cause actual results to differ materially. No representation is made that any of these statements or forecasts will come to pass or that any forecast results will be achieved. Forward-looking statements involve inherent known and unknown risks, uncertainties and contingencies because they relate to events and depend on circumstances that may or may not occur in the future and may cause the actual results, performance or achievements of the Company or the enlarged Group to be materially different from those expressed or implied by such forward-looking statements. Many of these risks and uncertainties relate to factors that are beyond the Company's or the enlarged Group's ability to control or estimate precisely, such as future market conditions, currency fluctuations, the behaviour of other market participants, the actions of regulators and other factors such as the Company's or the enlarged Group's ability to continue to obtain financing to meet its liquidity needs, changes in the political, social and regulatory framework in which the Company or the acquired businesses operate or in economic or technological trends or conditions. Past performance of the Company or the acquired businesses cannot be relied on as a guide to future performance. As a result, you are cautioned not to place undue reliance on such forward-looking statements contained in this presentation. Forward-looking statements speak only as of their date and the Company, Merrill Lynch International, HSBC Bank plc, J.P. Morgan Securities plc and BNP PARIBAS, their respective parent and subsidiary undertakings, the subsidiary undertakings of such parent undertakings, and any of such person's respective directors, officers, employees, agents, affiliates or advisers expressly disclaim any obligation to supplement, amend, update or revise any of the forward-looking statements made herein, except where it would be required to do so under applicable law.

Nothing in this presentation is intended as a profit forecast or profit estimate and no statement in this presentation should be interpreted to mean that the financial performance of the Company for the current or future financial years would necessarily match or exceed the historical published for the Company.

Any references to Solvency II relate to the relevant calculation for Phoenix Group Holdings.

The Company and its affiliates, advisors and representatives are not providing any advice on the suitability of the matters set out in this presentation or otherwise providing any investment advice or personal recommendations. Any presentations, research or other information communicated or otherwise made available in this presentation is incidental to the provisions of services by the Company and its affiliates, advisors and representatives and is not based on individual circumstances.

Merrill Lynch International, HSBC Bank plc and J.P. Morgan Securities plc (together with BNP PARIBAS, the "representatives"), each of which is authorised by the PRA and regulated in the United Kingdom by the PRA and the FCA, and BNP PARIBAS, which is supervised by the European Central Bank ("ECB") and the French Autorité de Contrôle Prudentiel et de Résolution ("ACPR") and the Autorité des marchés financiers ("AMF") and is authorised as a credit institution by the ECB and as an investment services provider by the ACPR in France (and whose London branch is lead-supervised by the ECB and the ACPR and is authorised by the ECB, the ACPR and the PRA and subject to limited regulation by the FCA and the PRA), are each acting for the Company and for no one else, and will not regard any other person as a client in and will not be responsible to anyone other than the Company for providing the protections afforded to their respective clients, nor for providing advice in connection with the transaction or arrangement referred to in this presentation.

The information contained in this presentation does not purport to be accurate or comprehensive and has not been independently verified. The information contained in this presentation is subject to updating, completion, revision, verification and amendment and such information may change materially. The Company is under no obligation to update or keep current the information contained in this presentation or in the presentation to which it relates and any opinions expressed in them are subject to change without notice. No representation or warranty, expressed or implied, is made by the Company and any of its affiliates as to the fairness, accuracy, reasonableness or completeness of the information contained herein and no reliance should be placed on it. Neither the Company nor any other person, including the representatives, accepts any liability for any loss howsoever arising, directly or indirectly, from reliance on this presentation. The Company and its affiliates, advisors and representatives (or any such persons' directors, officers, employees or affiliates) shall have no liability whatsoever (in negligence or otherwise) for any loss whatsoever arising from any use of this presentation. Persons reading this presentation must make all trading and investment decisions in reliance on their own judgement. This presentation has been prepared in compliance with English law and English courts will have exclusive jurisdiction over any disputes arising from or connected with this presentation.